SRPT Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of 16.72%. Sarepta Therapeutics's return on equity of 20.83% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Sarepta Therapeutics has a consensus price target of $155.00, signalling upside risk potential of 187.35%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.87 which suggests that it could grow by 63.72%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Sarepta Therapeutics has a beta of 0.930, which suggesting that the stock is 6.993% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Sarepta Therapeutics's net income of $159M is higher than Biomarin Pharmaceutical's net income of $124.9M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 23.66x while Biomarin Pharmaceutical's PE ratio is 26.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 3.16x versus 4.11x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of --. Sarepta Therapeutics's return on equity of 20.83% beat Edgewise Therapeutics's return on equity of --.

Sarepta Therapeutics has a consensus price target of $155.00, signalling upside risk potential of 187.35%. On the other hand Edgewise Therapeutics has an analysts' consensus of $42.78 which suggests that it could grow by 218.05%. Given that Edgewise Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Sarepta Therapeutics.

Sarepta Therapeutics has a beta of 0.930, which suggesting that the stock is 6.993% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are larger than Edgewise Therapeutics quarterly revenues of --. Sarepta Therapeutics's net income of $159M is higher than Edgewise Therapeutics's net income of -$39.7M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 23.66x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 3.16x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of -117.16%. Sarepta Therapeutics's return on equity of 20.83% beat Moderna's return on equity of -29.09%.

Sarepta Therapeutics has a consensus price target of $155.00, signalling upside risk potential of 187.35%. On the other hand Moderna has an analysts' consensus of $51.14 which suggests that it could grow by 106.9%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Sarepta Therapeutics has a beta of 0.930, which suggesting that the stock is 6.993% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Moderna quarterly revenues of $956M. Sarepta Therapeutics's net income of $159M is higher than Moderna's net income of -$1.1B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 23.66x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 3.16x versus 3.00x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 24.16% compared to Sarepta Therapeutics's net margin of 31.35%. Sarepta Therapeutics's return on equity of 20.83% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Sarepta Therapeutics has a consensus price target of $155.00, signalling upside risk potential of 187.35%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.43 which suggests that it could grow by 2.5%. Given that Sarepta Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Vertex Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.930, which suggesting that the stock is 6.993% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $658.4M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Sarepta Therapeutics's net income of $159M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 23.66x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 3.16x versus 11.44x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.